Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.48 |
| ▸ | SELE | P16581 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240133 | 0.89 | GAA (0.64) | GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL9433674 | 0.86 | ICAM1 (0.56) | GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL9433482 | 0.86 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL6240452 | 0.85 | KDM4E (0.53) | KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL9432926 | 0.83 | NPC1 (0.58) | KDM4ESMN1; SMN2ALDH1A1TP53NPC1 | |
| SCHEMBL7076857 | 0.82 | GAA (0.56) | GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL10371007 | 0.79 | NPC1 (0.46) | KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL6242047 | 0.78 | KDM4E (0.56) | GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL5735828 | 0.75 | KDM4E (0.51) | KDM4ESMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL27280522 | 0.74 | KDM4E (0.74) | GAAKDM4ESMN1; SMN2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | GAA 45/4885KDM4E 3961/4885SMN1; SMN2 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.